Company intelligence / Profile preview

Genome Biologics

Frankfurt, Hessen, Germany

Ownership: Private
Development stage: Other

Overview

Genome Biologics utilizes AI-driven GENIMAPS and accelerated therapeutic validation technology GENISYST to identify and repurpose drugs, with candidates reported to prevent COVID-19-induced cell death and hyperinflammation and preclinical data supporting cardiac regeneration and metabolic modulation[3][1][5].

Therapeutic areas: Infectious DiseasesCardiovascular
Modalities: RNA therapySmall moleculeBiologicAntisense oligonucleotide
Industry: Biotech

Partnerships

Johnson & Johnson Innovation - JLABS (incubator/resident program)[1][5]Goethe University Frankfurt (academic/funding)[1]Medical Research Council (MRC/UKRI)[1]Hessen Trade and Invest (government funding/support)[1]MedChem and Pharma (joint/in-house drug development)[1]

Beyond the preview

Go deeper on Genome Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genome Biologics.

Explore the full profile